labetalol has been researched along with Chemical and Drug Induced Liver Injury in 19 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Antihypertensive agents have been associated with adverse reactions that, if unrecognized by health practitioners, may have devastating consequences." | 2.38 | Fatal hepatotoxicity induced by hydralazine or labetalol. ( Stumpf, JL, 1991) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Greene, N | 1 |
| Fisk, L | 1 |
| Naven, RT | 1 |
| Note, RR | 1 |
| Patel, ML | 1 |
| Pelletier, DJ | 1 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Warner, DJ | 1 |
| Chen, H | 1 |
| Cantin, LD | 1 |
| Kenna, JG | 1 |
| Stahl, S | 1 |
| Walker, CL | 1 |
| Noeske, T | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Castiella, A | 1 |
| Iglesias, U | 1 |
| Zapata, E | 1 |
| Zubiaurre, L | 1 |
| Iribarren, A | 1 |
| Vicuña-Arregui, M | 1 |
| Ruiz-Clavijo-García, D | 1 |
| Zozaya-Urmeneta, JM | 1 |
| Bolado-Concejo, F | 1 |
| Nantes-Castillejo, O | 1 |
| Long, RC | 1 |
| Wofford, MR | 1 |
| Harkins, KG | 1 |
| Minor, DS | 1 |
| Kennedy, DL | 1 |
| Tanner, LA | 2 |
| Barash, D | 1 |
| Goetsch, RA | 1 |
| Chon, EM | 1 |
| Middleton, RK | 1 |
| Stronkhorst, A | 1 |
| Bosma, A | 1 |
| van Leeuwen, DJ | 1 |
| Stumpf, JL | 1 |
| Clark, JA | 1 |
| Zimmerman, HJ | 1 |
| Douglas, DD | 1 |
| Yang, RD | 1 |
| Jensen, P | 1 |
| Thiele, DL | 2 |
2 reviews available for labetalol and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Fatal hepatotoxicity induced by hydralazine or labetalol.
Topics: Aged; Chemical and Drug Induced Liver Injury; Humans; Hydralazine; Hypertension; Labetalol; Male | 1991 |
17 other studies available for labetalol and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
[Toxic hepatocellular hepatitis due to labetalol].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Asymptomatic Diseases; Chemical and Drug Induced Liv | 2015 |
[Cholestatic síndrome due to labetalol].
Topics: Adrenergic beta-Antagonists; Adult; Aortic Coarctation; Blood Coagulation Disorders; Chemical and Dr | 2010 |
Hepatocellular necrosis associated with labetalol.
Topics: Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Inj | 2007 |
National adverse drug event reporting.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Dietary Fibe | 1993 |
Labetalol hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Labetalol; Liver; Male; Middle Aged | 1992 |
A case of labetalol-induced hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Hypertension; Labetalol; Liver | 1992 |
Labetalol hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Humans; Labetalol; Product Surveillance, Postmarketing; Unit | 1991 |
Labetalol hepatotoxicity.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Female; Hepatitis, Vir | 1990 |
Fatal labetalol-induced hepatic injury.
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Hypertension; Labetalol; Liver Diseases; Mid | 1989 |
Labetalol hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Humans; Labetalol; Publishing | 1989 |